

PHARMACEUTICAL 2018

Wave Life Sciences Ltd. Rank 137 of 342









PHARMACEUTICAL 2018

Wave Life Sciences Ltd. Rank 137 of 342



The relative strengths and weaknesses of Wave Life Sciences Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Wave Life Sciences Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 58% points. The greatest weakness of Wave Life Sciences Ltd. is the variable Research and Development, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 95% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	150,488
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,621
Liabilities, Non-Current	14,534
Other Assets	4,021
Other Compr. Net Income	407
Other Expenses	708
Other Liabilities	0
Other Net Income	1,253
Other Revenues	3,704
Property and Equipment	27,334
Research and Development	79,309
Selling, General and Administrative Expense	26,975

Output Variable	Value in 1000 USD
Assets	181,843
Liabilities	34,155
Expenses	106,992
Revenues	3,704
Stockholders Equity	147,688
Net Income	-102,035
Comprehensive Net Income	-101,832
Economic Capital Ratio	141%

